지원되지 않는 브라우저를 실행하고 있습니다. 브라우저를 업그레이드하세요. 닫기

이메일 구독

Never miss the latest news and offers - subscribe now!

Never miss the latest news and offers - subscribe now!

개인정보 취급 방침 및 쿠키

By browsing this site you accept cookies used to improve and personalize our services and marketing. Learn more about our Data Privacy Policy, including cookies, by clicking the Policy button.

By browsing this site you accept cookies used to improve and personalize our services and marketing. Learn more about our Data Privacy Policy, including cookies, by clicking the Policy button.

Integrated Solutions for Gene Therapy

November 1, 2019

 

What Is an Integrated Solution?

 

Integrated manufacturing solutions for gene therapy provide scalable well characterized processes where individual unit operations are synchronized and coordinated to deliver a defined, consistent result. Integrated solutions provide a comprehensive outcome when multiple disciplines are combined to achieve distinct results. They help simplify and streamline manufacturing processes, expecditing time to market, as well as reducing overall cost of goods.

 

Gene therapy  is relatively new and the industry is still evolving to manufacture consistent, scalable and cost-effective product to meet commercial demand. Current practices used by the biopharmaceutical industry are unable to meet manufacturing demand and deliver low yield product. This is not a problem for some medicinal targets such as rare genetic disorders of eye where only small percentage of population is impacted and doses needed per patient are low (~1011 vg AAV/eye). On the other hand, predominant diseases like hemophilia and Duchenne muscular dystrophy where both patient population and number of doses require per patient is high (~1015 vg AAV/patient), require larger batch sizes to meet the demand. 

 

Importance of Integrated Solutions for Gene Therapy Commercialization

 

Gene therapy commercialization is comparable to other therapeutics where the manufacturer focuses on managing and balancing risk of investment during development phase. Investing very early in manufacturing technology before the product has been fully characterized can lead to issues of manufacturing the incorrect product. Alternatively, investing late in development can lead to challenges of scaling-up the process to meet the demand. Production processes could also become risky and expensive. There are several decisions a manufacturer needs to make at every step from early development, through to manufacturing stages.

 

One of the core manufacturing decisions a company needs to make is either to work with a contract development and manufacturing organization (CDMO) or to invest in in-house manufacturing capabilities. Irrespective of which route a manufacturer takes, cost-effective and efficient manufacturing processes can be implemented by using integrated manufacturing solutions.

 

At present, many gene therapy products are being manufactured using traditional practices. These involve manual open steps, which results in process inefficiency and heightened risk of product contamination. Together these problems can be resolved by incorporating integrated solutions, such as scalable single-use, automated and closed system platforms.

 

Benefits of integrated solutions include:

 

  • Improved process efficiency through using single-use components, which decreases the time required for cleaning and validating a cleaning cycle. 
  • Reduced operator intervention and minimized operator error due to automated processes 
  • Improved product reproducibility and decreased risk of facing batch failure due to the consistent process control provided by automated processes. 
  • Consistent and contamination risk free products are produced by co-ordinating and connecting individual process steps in continuous modes, together with scalable automated, single-use platforms 

 

Applying Integrated Solutions to Gene Therapy Manufacturing

 

Despite the fact that integrated solutions can offer substantial value to manufacturing process, it requires experience and expertise associated with manufacturing process, equipment automation and engineering for operational execution. The most proficient way of incorporating integrated solutions is to work with end-to-end solution providers who have skilled process experts and resources to manage the entire project. The provider also ensures the project is managed based on process requirements rather than fitting the process on selected equipment by offering compatible solutions.

 

Modular integrated solutions  can add further benefits to gene therapy manufacturing. These include delaying the initial capital investment and saving time by providing cleanrooms fitted with automated instruments required for their unique manufacturing process. These pre-fabricated containment cleanroom systems (G-CON PODs) will provide a flexible and speedy approach to fulfill industry and regulatory authorities’ demand for cleanrooms at lower capital cost. In addition, they facilitate more time to evaluate clinical trial data to make an informed decision before proceeding to commercialization.

 

Pall’s integrated solutions team combines engineering expertise, in-depth industry knowledge and a diverse portfolio of equipment to deliver end-to-end solutions within time and budget. It is important to consider that the quality of an integrated solution depends on a well characterized manufacturing process. For gene therapy manufacturers who seek further expertise to develop their processes, Pall’s AcceleratorSM Process Development Services  team is available to apply their expertise to develop and scale-up processes for manufacturing viral vectors.

 

Want to learn more about end-to-end processes for gene therapy manufacturing? Read more in the case study: End-To-End Process for Large Scale Adenovirus Manufacturing for Gene Therapy  to gain a deeper understanding of the viral vector manufacturing process developed by Pall’s Accelerator Process Development Services team to fulfill manufacturers need of clinical grade material for Phase I trial.

 

 

gene therapy integrated solutions

Grishma Patel – Senior Scientist, Process Development Services

Grishma Patel is a Senior Scientist for the Process Development Services (PDS) team at Pall Biotech. She holds a Master of Science in Cell & Molecular Biology and has over 10 years experience scaling-up adherent cell culture processes. When not at work, Grishma loves to spend time with her family, play board games and travel.
Grishma Patel is a Senior Scientist for the Process Development Services (PDS) team at Pall Biotech. She holds a Master of Science in Cell & Molecular Biology and has over 10 years experience scaling-up adherent cell culture processes. When not at work, Grishma loves to spend time with her family, play board games and travel.
더 읽어보기
  • Category
  • Author
  • Sort By
Results